Irritable Bowel Syndrome Partnering 2007-2012

CurrentPartnering, August 2012, Pages: 100

The Irritable Bowel Syndrome Partnering 2007-2012 report provides understanding and access to the irritable bowel syndrome partnering deals and agreements entered into by the worlds leading healthcare companies.

- Trends in irritable bowel syndrome partnering deals
- Top irritable bowel syndrome deals by value
- Deals listed by company A-Z, industry sector, stage of development, technology type

The Irritable Bowel Syndrome Partnering 2007-2012 provides understanding and access to the irritable bowel syndrome partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of irritable bowel syndrome partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors irritable bowel syndrome technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 30 links to online copies of actual irritable bowel syndrome deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of irritable bowel syndrome partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in irritable bowel syndrome partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading irritable bowel syndrome deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of irritable bowel syndromepartnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of irritable bowel syndrome technologies and products.

Report scope

Irritable Bowel Syndrome Partnering 2007-2012 is intended to provide the reader with an in-depth understanding and access to irritable bowel syndrome trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

- Trends in irritable bowel syndrome dealmaking in the biopharma industry since 2007
- Access to summary headline, upfront, milestone and royalty data
- Access to over 30 irritable bowel syndrome contract documents
- The leading irritable bowel syndrome deals by value since 2007

In Irritable Bowel Syndrome Partnering 2007-2012, the available deals are listed by:

- Headline value
- Upfront payment value
- Royalty rate value
- Company A-Z
- Industry sector
- Stage of development at signing
- Deal component type
- Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

Irritable Bowel Syndrome Partnering 2007-2012 provides the reader with the following key benefits:

- In-depth understanding of irritable bowel syndrome reflux deal trends since 2007
- Access to summary headline, upfront, milestone and royalty data
- Comprehensive access to over 30 actual irritable bowel syndrome deals entered into by the world’s biopharma companies since 2007
- Insight into key deal terms included in contracts, where disclosed
- Understand the key deal terms companies have agreed in deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in irritable bowel syndrome partnering

- 2.1. Introduction
- 2.2. Irritable bowel syndrome partnering over the years
- 2.3. Bigpharma irritable bowel syndrome dealmaking activity
- 2.4. Irritable bowel syndrome partnering by deal type
- 2.5. Irritable bowel syndrome partnering industry sector
- 2.6. Irritable bowel syndrome partnering by stage of development
- 2.7. Irritable bowel syndrome partnering by technology type
- 2.8. Disclosed financial deal terms for irritable bowel syndrome partnering
- 2.8.1 Irritable bowel syndrome headline values
- 2.8.2 Irritable bowel syndrome upfront payments
- 2.8.3 Irritable bowel syndrome milestone payments
- 2.8.4 Irritable bowel syndrome royalty rates

Chapter 3 – Leading irritable bowel syndrome deals

- 3.1. Introduction
- 3.2. Top irritable bowel syndrome deals by value
- 3.3. Top irritable bowel syndrome deals involving bigpharma

Chapter 4 – Dealmaking directory

- 4.1. Introduction
- 4.2. Company A-Z
- 4.3. By deal type
- Asset purchase
- Bigpharma outlicensing
- Co-development
- Collaborative R&D
- Co-market
- Contract service
- Co-promotion
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Settlement
- Spin out
- Sub-license
- Supply
- Termination
- 4.4. By industry sector
- Academic
- Bigpharma
- Biotech
- Drug delivery
- Medical device
- Diagnostic
- Generic pharma
- Government
- Non-profit
- Pharmaceutical
- Research tools
- Services
- Specialty pharma
- 4.5. By stage of development
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Registration
- Marketed
- 4.6. By technology type
- Analysis
- Animal models
- Assays
- Bioinformatics
- Biological compounds
- Biomarkers
- Biomaterials
- Cell culture
- Cell therapy
- Clinical testing
- Diagnostic - companion
- Devices
- Diagnostics
- Discovery tools
- DNA probes
- Drug delivery
- Enabling technology
- Epigenetics
- Equipment
- Facilities
- Gene therapy
- Genomics
- Imaging
- Industrial chemicals
- In vitro models
- Monoclonal antibodies
- Nanotechnology
- Oligonucleotide
- Peptides
- Personalised medicine
- Processes
- Proteomics
- Radio/Chemo-therapy
- Recombinant DNA
- Research services
- Research supplies
- RNA therapeutics
- Screening
- Small molecules
- Stem cells
- Vaccines

Chapter 5 – Partnering resource center

- 5.1. Online partnering
- 5.2. Partnering events
- 5.3. Further reading on dealmaking

Appendices

- Appendix 1 – Deal type definitions

About Wildwood Ventures

- Current Partnering
- Current Agreements
- Recent titles from CurrentPartnering
- Order Form – Reports

Table of figures

- Figure 1: irritable bowel syndrome partnering since 2007
- Figure 2: Bigpharma – top 50 – irritable bowel syndrome deals 2007 to 2011
- Figure 3: Bigpharma irritable bowel syndrome deal frequency – 2007 to 2011
- Figure 4: Irritable bowel syndrome partnering by deal type since 2007
- Figure 5: Irritable bowel syndrome partnering by industry sector since 2007
- Figure 6: Irritable bowel syndrome partnering by stage of development since 2007
- Figure 7: Irritable bowel syndrome partnering by technology type since 2007
- Figure 8: Irritable bowel syndrome deals with a headline value
- Figure 9: Irritable bowel syndrome deals with upfront payment values
- Figure 10: Irritable bowel syndrome deals with milestone payments
- Figure 11: Irritable bowel syndrome deals with royalty rates, %
- Figure 12: Top irritable bowel syndrome deals by value since 2007
- Figure 13: Top irritable bowel syndrome deals signed by bigpharma value since 2007
- Figure 14: Online partnering resources
- Figure 15: Forthcoming partnering events
- Figure 16: Deal type definitions

The Irritable Bowel Syndrome Partnering 2007-2012 report provides understanding and access to the irritable bowel syndrome partnering deals and agreements entered into by the worlds leading healthcare companies

On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service

Customers who bought this item also bought

• Annual Deal Report - Defense
• November Monthly Deals Roundup - Defense
• December Monthly Deals Roundup - Defense
• Monthly Defense Deals Roundup - May, 2012
• October Monthly Deals Roundup - Defense
• Monthly Deals Roundup, Q1 - Defence
• Annual Deal Report – Defense
• Q2, Monthly Deals Roundup - Defense
• February Monthly Deals Roundup – Defense
• 06 - Monthly Deals Roundup - Defense